A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Trial Profile

A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Aug 2018

At a glance

  • Drugs Selinexor (Primary) ; Bortezomib; Dexamethasone
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms BOSTON
  • Sponsors Karyopharm Therapeutics
  • Most Recent Events

    • 15 Jun 2018 Results published in the Karyopharm Therapeutics Media Release
    • 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 10 May 2018 According to a Karyopharm Therapeutics media release, the company plans to complete enrolment in this trial by the end of 2018, with top-line data anticipated in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top